(Q38379888)

English

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

scientific article published on 31 July 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial (English)

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

François Guilhot

object named as

François Guilhot

1

0 references

Richard A. Larson

object named as

Richard A Larson

3

0 references

author name string

Insa Gathmann

4

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Charlene So

5

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Roger Waltzman

6

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Stephen G O'Brien

7

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

publication date

31 July 2009

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

94

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

12

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

1669-1675

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

6 September 2017

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

6 September 2017

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

6 September 2017

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

6 September 2017

Cytokine therapeutics: lessons from interferon alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

6 September 2017

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

23 June 2018

IFNalpha activates dormant haematopoietic stem cells in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

31 August 2018

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

31 August 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

31 August 2018

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791923

3 December 2018

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2009.010629

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38379888&oldid=1939892524"